Abstract
DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.
Original language | English (US) |
---|---|
Pages (from-to) | 295-297 |
Number of pages | 3 |
Journal | Trends in Pharmacological Sciences |
Volume | 40 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Externally published | Yes |
Keywords
- checkpoint kinase 1 inhibitor
- immune checkpoint blockade
- PARP inhibitor
- PD-1
- PD-L1
- SCLC
ASJC Scopus subject areas
- Toxicology
- Pharmacology